Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abilar Wound Balm is a topical resin-based medical device developed by Repolar Pharmaceuticals for the treatment of infected and non-infected wounds. Its active ingredient is refined resin from Norway spruce (*Picea abies*), collected from Finnish Lapland and formulated at a 10% concentration in a petrolatum-based salve. The product works through multiple mechanisms: it creates a physical protective barrier against bacteria and yeasts that cause skin infections, provides intrinsic antimicrobial and anti-inflammatory effects, and promotes wound healing by maintaining an optimal moist wound environment. It is indicated for both acute and chronic wounds, including pressure ulcers, diabetic ulcers, leg ulcers, surgical wound complications, burns, lacerations, abrasions, and fissures. Abilar is classified as a CE-marked Class IIb medical device and is approved for both professional healthcare and home use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Abilar Wound Balm.